Advertisement - see our Ad Policy
Advertisement - see our Ad Policy

Shockwave Therapy for Peyronie’s Disease


Peyronie’s Disease (PD) is a connective tissue disorder involving the growth of fibrous plaques, or scar tissue, in the soft tissue of the penis. It can cause curved, painful erections, difficulty ejaculating, and difficulty urinating. It may affect up to 5% of adult males in the United States.

Treatment options are limited. Several drugs have been shown to be effective; for cases that do not respond to drug therapies, surgical intervention may be possible.

Low-Intensity Extracorporeal Shockwave Therapy (LI-ESWT) – commonly called shockwave therapy – offers a non-invasive alternative treatment option. It has shown promising results in treating PD1 2 3, as well as erectile dysfunction. The therapy works by breaking down plaque and scar tissue, and by encouraging the growth of healthy new tissue and blood vessels (angiogenesis).

Shockwave therapy is generally administered in a clinical setting using commercial medical devices. It requires a series of treatments – generally over 6-12 weeks – using a medical device that administers sonic “shockwaves” to the penis. In 2020, a home treatment device called the Phoenix became available; according to its developers, it provides the same treatment protocol as clinical equipment.


  1. Chung, Eric. “Peyronie’s disease and low intensity shock wave therapy: Clinical outcomes and patient satisfaction rate in an open-label single arm prospective study in Australian men.” Korean Journal of Urology. Nov 2015.
  2. Di Mauro, Marina; Russo, Giorgio Ivan; et al. “Extracorporeal Shock Wave Therapy in Peyronie’s Disease: Clinical Efficacy and Safety from a Single-Arm Observational Study.” The World Journal of Men’s Health. Mar 2019.
  3. Shimpi, Rajendra Kashinath; Jain, Ravi Jineshkumar. “Role of extracorporeal shock wave therapy in management of Peyronie’s disease: A preliminary report.” Urology Annals. Oct-Dec 2016.

Comments are closed.